Oxazepam
Product Description
F.I.S. Fabbrica Italiana Sintetici SpA
-
IT
-
2015On CPHI since
-
3Certificates
-
1000 - 4999Employees
Company types
Categories
F.I.S. Fabbrica Italiana Sintetici SpA
-
IT
-
2015On CPHI since
-
3Certificates
-
1000 - 4999Employees
Company types
More Products from F.I.S. Fabbrica Italiana Sintetici SpA (26)
-
Product Gabapentin
FIS produces a wide range of API's which includes Gabapentin. It is commercially available. Contact us for more information. -
Product Indomethacin
FIS produces a wide range of API's which includes Indomethacin. It is commercially available. Contact us for more information. -
Product Ketazolam
FIS produces a wide range of API's which includes Ketazolam. It is commercially available. Contact us for more information. -
Product Midazolam
FIS produces a wide range of API's which includes Midazolam. It is commercially available. Contact us for more information. -
Product Nitrazepam
FIS produces a wide range of API's which includes Nitrazepam. It is commercially available. Contact us for more information. -
Product Olopatadine Hydrochloride
FIS produces a wide range of API's which includes Olopatadine Hydrochloride. It is commercially available. Contact us for more information. -
Product Pentazocine
FIS produces a wide range of API's which includes Pentazocine. It is commercially available. Contact us for more information. -
Product Prazepam
FIS produces a wide range of API's which includes Prazepam. It is commercially available. Contact us for more information. -
Product Quetiapine Fumarate
FIS produces a wide range of API's which includes Quetiapine Fumarate. It is commercially available. Contact us for more information. -
Product Progesterone
FIS produces a wide range of API's which includes Progesterone. It is commercially available. Contact us for more information. -
Product Temazepam
FIS produces a wide range of API's which includes Temazepam. It is commercially available. Contact us for more information.
F.I.S. Fabbrica Italiana Sintetici SpA resources (3)
-
News Revenues up 20% in 2022
The growth trend remains in the first quarter of 2023: revenues of €153 million, up 31% compared to the first quarter of 2022 -
News FIS joins Energize
Energize is the international programme discussed at COP27 that aims to promote the use of renewable energy and to reduce greenhouse gas emissions in the chemical and pharmaceutical sector. -
News FIS redefines the structure of its commercial department
Luca Parlanti and Gianluca Schiavoni join FIS as directors of the new generics and custom divisions
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance